Sandbox shengshi: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 2: | Line 2: | ||
{{Meningitis}} | {{Meningitis}} | ||
{{CMG}}; | {{CMG}}; {{AE}} {{CZ}} {{SS}} | ||
==Medical Therapy== | ==Medical Therapy== | ||
Line 117: | Line 117: | ||
<sup>†</sup>Add '''''[[Ampicillin]] 2 g IV q4h''''' ('''''50 mg/kg IV q6h''''' for children) if meningitis caused by ''[[Listeria monocytogenes]]'' is also suspected. | <sup>†</sup>Add '''''[[Ampicillin]] 2 g IV q4h''''' ('''''50 mg/kg IV q6h''''' for children) if meningitis caused by ''[[Listeria monocytogenes]]'' is also suspected. | ||
====Healthcare-Associated Meningitis==== | ====Healthcare-Associated Meningitis==== | ||
Line 149: | Line 147: | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftazidime]] 2 g IV q8 h'''''<BR> ''OR''<BR>▸ '''''[[Cefepime]] 2 g IV q8h'''''<BR>▸ '''''[[Meropenem]] 2 g IV q8h''''' | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftazidime]] 2 g IV q8 h'''''<BR> ''OR''<BR>▸ '''''[[Cefepime]] 2 g IV q8h'''''<BR>▸ '''''[[Meropenem]] 2 g IV q8h''''' | ||
|} | |} | ||
|} | |||
<SMALL>Adapted from ''Advances in treatment of bacterial meningitis. Lancet. 2012;380(9854):1693-702.''</SMALL><ref name="van de Beek-2012">{{Cite journal | last1 = van de Beek | first1 = D. | last2 = Brouwer | first2 = MC. | last3 = Thwaites | first3 = GE. | last4 = Tunkel | first4 = AR. | title = Advances in treatment of bacterial meningitis. | journal = Lancet | volume = 380 | issue = 9854 | pages = 1693-702 | month = Nov | year = 2012 | doi = 10.1016/S0140-6736(12)61186-6 | PMID = 23141618 }}</ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} |
Revision as of 20:10, 14 January 2014
Meningitis Main Page |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Cafer Zorkun, M.D., Ph.D. [2] Sheng Shi, M.D. [3]
Medical Therapy
Empiric Treatment
- Adjunctive Dexamethasone (0.15 mg/kg IV q6h for 2—4 days) is recommended for both children and adult patients with acute bacterial meningitis.
Community-Acquired Meningitis
|
|
†Add Ampicillin 2 g IV q4h (50 mg/kg IV q6h for children) if meningitis caused by Listeria monocytogenes is also suspected.
Healthcare-Associated Meningitis
Adapted from Advances in treatment of bacterial meningitis. Lancet. 2012;380(9854):1693-702.[1] References |